The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II ... s archrival in the obesity space, Eli Lilly LLY, also declined 4.2% on Friday ...

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand ...

Comparatively, Eli Lilly’s orforglipron demonstrated superior ... compared to 0% for placebo. A capsule to tablet PK study designed to explore a new tablet formulation of GSBR-1290 demonstrated ...

also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. UTHR is a Zacks Rank #2 (Buy) stock, with a Growth ...

You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo ... The company also is developing VK2735 in an oral tablet formulation, and that candidate just entered a phase ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...